Helius Medical Technologies said yesterday its subsidiary NeuroHabilitation Corporation inked a cost sharing contract with the U.S. Army Medical Research and Materiel Command to support a trial of its portable neuromodulation stimulator.
The device is designed to treat balance disorder in patients with mild to moderate traumatic brain injury, the Newton, Penn.-based company said.
“This important contract represents the dedication and commitment that Helius and the USAMRMC have towards delivering a therapy for traumatic brain injury patients. There is a large unmet need in both the war fighter and civilian population and this is a big step forward,” CEO Phil Deschamps said in a press release.
Helius’ non-invasive device induces neuromodulation through stimulation of cranial nerves found in the tongue, the company said.
“The Army remains committed to supporting evidence-based solutions for our wounded warriors. Our long term commitment to the PoNS technology will help advance the clinical trials and FDA submission process. If successful, we will be able to deploy this technology to our service members,” USAMRMC principal assistant for acquisition Dr. Kenneth Bertram said in a prepared statement.
In April, Helius got the go-ahead from the FDA to begin enrolling patients in a clinical trial of its portable neuromodulator in patients with chronic balance disorders due to mild-to-moderate brain injury.
